



Principal Investigator

The University of Tokyo Ken Okamoto


Adopted Theme

Development and Commercialization of an Oral Drug for Sarcopenia-related Muscle Weakness and Endurance Loss

Subject of Research

Development and Commercialization of an Oral Drug for Sarcopenia-related Muscle Weakness and Endurance Loss

Overview



This project aims to develop and commercialize an oral drug that improves muscle strength and endurance associated with sarcopenia. By enhancing the purine salvage pathway, it uniquely boosts ATP production and directly improves muscular energy metabolism. Utilizing existing drugs ensures a high safety profile and the potential for rapid clinical translation. Led by the University of Tokyo and supported by an academia-industry partnership, the project will establish a startup in 2025 and pursue an M&A exit within seven years. Global expansion is planned through collaboration with domestic and international VCs and pharmaceutical companies, addressing the growing medical needs of aging populations worldwide.

Business Models (when applying)

This project adopts a business model focused on repurposing existing drugs to develop a safe and fast-acting oral therapy for sarcopenia, an underserved market. By generating robust preclinical data and securing strong IP, we aim to establish strategic partnerships with pharmaceutical companies and VCs, ultimately monetizing through licensing deals or an M&A exit.

Activity Planning (when applying)

This project aims to commercialize an oral drug that improves muscle strength and endurance associated with sarcopenia. In FY2025, we plan to complete preclinical studies and establish a startup. Led by the principal investigator, we will validate the efficacy of ATP production enhancement via salvage pathway activation using animal models, while advancing fundraising from domestic and global VCs. In parallel, we will define the product concept, build an IP strategy, prepare for regulatory engagement, and secure executive talent. With an eye toward international market expansion, we will leverage support networks such as StartX and aim for an M&A exit within seven years.